Theriva Biologics (TOVX) vs Tempest Therapeutics (TPST)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Theriva Biologics (TOVX) has outperformed Tempest Therapeutics (TPST) over the past year, losing 45.5% versus a loss of 91.8%. Over five years, TPST leads with a -99.8% price change compared with -99.9% for TOVX. Tempest Therapeutics is the larger company by market cap ($5.7 million vs $5.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | TOVX | TPST |
|---|---|---|
| Share price | $0.12 | $0.287 |
| Market cap | $5.51M | $5.74M |
| 1-day change | -6.25% | -6.18% |
| YTD return | -42.86% | -90.00% |
| 1-year return | -45.45% | -91.80% |
| 5-year return | -99.86% | -99.77% |
| P/E ratio (TTM) | 0.10 | — |
| EPS (TTM) | $1.15 | $-3.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-23.74M | $-26.26M |
| 52-week high | $0.49 | $4.22 |
| 52-week low | $0.12 | $0.28 |
| Distance from 52-week high | -75.51% | -93.20% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1983.33% | +2339.02% |
| Average volume | 2.02M | 2.56M |
| Shares outstanding | 45.89M | 20.00M |
| Employees | 15 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TOVX has outperformed TPST by 46.3 percentage points over the past year.
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
About Tempest Therapeutics
TPST stock →Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
TOVX vs TPST FAQ
Which is bigger, Theriva Biologics or Tempest Therapeutics?
Tempest Therapeutics (TPST) is larger, with a market capitalization of $5.74M compared with $5.51M for Theriva Biologics (TOVX).
Which stock has performed better over the past year, TOVX or TPST?
TOVX returned -45.45% over the past 12 months, compared with -91.80% for TPST (price return, excluding dividends). Past performance does not predict future results.
Are Theriva Biologics and Tempest Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.